Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 26/10/2020
SIETES contiene 93135 citas

<< anterior 21 a 40 de 514 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Weir MR, Bakris GL, Bushinsky DA, Garza DG, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, for the OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalaemia receiving RAAS inhibitors. N Engl J Med 2015;372:211-21. [Ref.ID 98710]
22. Cita con resumen
Anónimo. FDA approves anti-clotting drug Savaysa. U.S. Food and Drug Administration 2015:8 de enero. [Ref.ID 98703]
23. Cita con resumen
Anónimo. Interferon beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome. Drug Safety Update 2014;8:A1. [Ref.ID 98101]
24. Cita con resumen
Wright DFB, Al-Sallami HS, Duffull SB. Is the dose of dabigatran really more predictable than warfarin?. Br J Clin Pharmacol 2013;76:997-8. [Ref.ID 96634]
25.Tiene citas relacionadas
de Zeeuw D. The end of dual therapy with renin-angiotensin-aldosterone system blockade?. N Engl J Med 2013;369:1960-2. [Ref.ID 96540]
26.Tiene citas relacionadas Cita con resumen
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P, for the VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-903. [Ref.ID 96537]
27. Cita con resumen
Bastiansen A, Eggert S, Pedersen E. Pharmacokinetics of terbutaline in chronic kidney disease. Eur J Clin Pharmacol 2013;69:1951-4. [Ref.ID 96502]
29. Cita con resumen
Hosseinjani H, Moghaddas A, Khalili H. N-acetylcysteine for the prevention of non-constrast media agent-induced kidney injury: from preclinical data to clinical evidence. Eur J Clin Pharmacol 2013;69:1375-90. [Ref.ID 95850]
Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R. Acute kidney injury: an increasing global concern. Lancet 2013;382:170-9. [Ref.ID 95829]
Boyer A, Gruson D, Bouchet S, Clozeau B, Hoan-Nam B, Vargas F, Gilles H, Molimard M, Rogues A-M, Moore N. Aminoglycosides in septic shock - An overview, with specific consideration given to their nephrotoxic risk. Drug Saf 2013;36:217-30. [Ref.ID 95310]
32. Cita con resumen
Leonard CE, Freeman CP, Newcomb CW, Reese PP, Herlim M, Bilker WB, Hennessy S, Strom BL. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf 2012;21:1155-72. [Ref.ID 93987]
33. Cita con resumen
Keir L, van Moorsel F, Saleem MA, Richards A. Anti-VEGF treatment. Beware renal adverse effects. BMJ 2012;344:26-7. [Ref.ID 93192]
34.Tiene citas relacionadas Cita con resumen
Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 2012;60:390-41. [Ref.ID 92942]
35. Cita con resumen
Anónimo. Fénofibrate: perturbation de la fonction rénale. Prescrire 2011;31:190. [Ref.ID 90307]
36. Cita con resumen
Anónimo. Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther 2010;52:25-7. [Ref.ID 88429]
37. Cita con resumen
Anónimo. Propolis: réactions d'hypersensibilité. Prescrire 2010;30:190. [Ref.ID 88019]
38. Cita con resumen
Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide — The FDA’s review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7. [Ref.ID 87929]
40. Cita con resumen
Lohmander LS, Roos EM. Clinical update: treating osteoarthritis. Lancet 2007;370:2082-4. [Ref.ID 81846]
Seleccionar todas
<< anterior 21 a 40 de 514 siguiente >>